Express Mail No.: EV 335 859 226 US



pplication of: Roemer et al.

Confirmation No.: 8340

Application No.: 10/032,585

Group Art Unit: 1636

Filed: December 20, 2002

Examiner: To be assigned

For: GENE DISRUPTION

Attorney Docket No.: 10182-016-999

METHODOLOGIES FOR DRUG

TARGET DISCOVERY

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 and § 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to the references listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant."

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant submits herewith several pages of a "revised form PTO-1449" entitled "List of References Cited by Applicant." Legible copies of References AA-DN are being submitted herewith.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to JONES DAY Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Date January 30, 2004

Respectfully submitted

20742

(Dec. N

Laura A. Coruzzi

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 790-9090

Attachments

JAN 3 0 2004

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10182-016-999	10/032,585
APPLICANT	
Roemer et al.	
FILING DATE	GROUP
December 20, 2002	1636

IIS	PA	TENT	DOCUM	PLATE

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCL	FILING DATE IF APPROPRIATE
	AA	60/123,807	3/11/99	Berlin et al.		<u> </u>	
	AB	US2001/0031724	10/18/01	Roemer et al.			
	AC	5,464,758	11/7/95	Gossen et al.			
	AD	5,569,588	10/29/96	Ashby et al.			
	AE	5,604,097	02/18/97	Brenner S.			
	AF	5,614,377	3/25/97	Bulawa			
	AG	5,635,400	6/3/97	Brenner S.			
	AH	5,654,413	8/5/97	Brenner S.			
	AI	5,770,358	6/23/98	Dower et al.			
	AJ	5,801,015	9/1/98	Cottarel et al.			
	· AK	5,807,522	9/15/98	Brown et al.			
	AL	5,821,038	10/13/98	Fleer et al.			
	AM	5,821,353	10/13/98	Douglas et al.			
	AN	5,846,719	12/08/98	Brenner et al.			
	AO	5,876,931	3/2/99	Holden			
	AP	5,939,306	8/17/99	Alex et al.			
	AQ	5,972,708	10/26/99	Sherratt et al.			
	AR	5,976,866	11/2/99	Heidler et al.			
	AS	6,004,779	12/21/99	Bradley et al.			
	AT	6,015,689	1/18/00	Okado et al.			
·	AU	6,022,949	2/8/00	Okado et al.			
	AV	6,046,000	4/4/00	McCarthy et al.			
	AW	6,046,002	4/4/00	Davis et al.			
	AX	6,096,511	8/1/00	Nielsen-Kahn et al.			
	AY	6,117,641	9/12/00	Berlin et al.			
	AZ	6,138,077	10/24/00	Brenner. S.			
	BA	6,140,489	10/31/00	Brenner S.			
	BB	6,150,516	11/21/00	Brenner et al.			
	ВС	6,194,166	2/27/01	Okado et al.			
	BD	6,228,579	5/8/01	Zyskind et al.			

DIFE	BE	6,232,074	5/15/01	Dawson et al.				
14-2-0	BF	6,248,525	6/19/01	Nilsen				
3 0 2004	BG	6,277,564	8/21/01	Berlin et al.				
ADEMAC!	ВН	6,280,963	8/28/01	Koltin et al.				
-	BI	6,294,651	9/25/01	Okado et al.				
•	BJ	6,303,115	10/16/01	Natsoulis				
	BK	6,320,033	11/20/01	Bourbonnais et al.				
	DK	6,505,126	1/7/03	Hare et al.				
		F	OREIGN 1	PATENT DOCUMENTS	!			\neg
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS S		
	·BL	WO 95/06132	3/2/95	PCT			YES	NO
	BM	WO 97/16540	5/9/97	PCT				
	BN	WO 97/48822	12/24/97	PCT			11	
	ВО	WO 98/21366	5/22/98	PCT			-	
	BP	WO 98/44135	10/8/98	PCT (In German w/ English Abstract)				x
	BQ	WO 98/45426	10/15/98	PCT				
	BR	WO 99/10474	3/4/99	PCT				
	BS	WO 99/23244	5/14/99	PCT				
	BT	WO 99/31269	6/24/99	PCT				
	BU	WO99/52926	10/21/99	PCT				
	BV	WO 00/09695	2/24/00	PCT				
	BW	WO 00/15838	3/23/00	PCT				
	BX	WO 00/34481	6/15/00	PCT				
	BY	WO 00/36082	6/20/00	PCT				
	BZ	WO 00/39287	7/6/00	PCT				
	CA	WO 00/44906	8/3/00	PCT				
	СВ	WO 00/53781	9/14/00	PCT				
	CC	WO 00/68420	11/6/00	PCT				
	CD	WO 00/75305	12/14/00	PCT				
	CE	WO 01/02550	1/11/01	PCT				
	CF	WO 01/14533	3/1/01	PCT				
	CG	WO 01/77295	10/18/01	PCT				
	СН	EP 799 897	10/8/97	EU			1	
	CI	EP 816 511	01/07/98	EU			1	
	CJ	EP 982 401	3/1/00	EU			+	
	DL	DE 100 23 130 A1	11/22/01	Germany			1	x
	DM	WO 01/85989	11/15/01	PCT (in German w/ English Abstract)			+	x
		<u> </u>	-L	- 2 -		NY2 - 13	01/08	

IPE	DN	WO 02/064766	8/22/02	PCT					
	6 O	THER REFEREN	CES (Inclu	ding Author, Title, D	ate, Pertinent Pages,	Etc.)	·		
3 0 ₂₀₀₄	TCK W	essential for growth.	FEMS Yeast R	esearch 2001, 1411:1-9	C-3 sterol dehydrogenase (
DEMAND!	& CL	fumigatus pathogenic	ty. Mol Micro	biol. 2000 Jun;36(6):137					
	CM	assembly. Mol Cell E	iol. 1993 Oct;	13(10):6346-56	glycoprotein involved in ce				
	CN	Oct;182(20):5730-6			oid Candida albicans. J Bad				
_	СО	Jul;134(3):717-28			Candida albicans. Genetics				
	СР	Saccharomyces cerev	siae. Yeast. 1	997 Jul;13(9):837-48	moter system for modulated				
	CQ	Yeast. 1999 Oct;15(1	4):1541-53		for gene disruption in Saccl				
	CR	73(suppl.1):S335-S34	2		of Candida albicans. Can. J.				
	CS	other proteins. Proc N	atl Acad Sci U	S A. 1999 Jan 19;96(2):5					
	CT	Hull et al. Evidence for mating of the "asexual" yeast Candida albicans in a mammalian host. Science. 2000 Ju 14;289(5477):307-10							
	CU	Katinka MD et al. Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature. 2001 Nov 22;414(6862):450-3							
	CV	Kwon-Chung K. Gene disruption to evaluate the role of fungal candidate virulence genes. Curr Opin Microbiol. 1998 Aug;1(4):381-9. Review							
	CW	Magee and Scherer, Genome mapping and gene discovery in Candida albicans. ASM News. 1998 Nov; 64:505-11							
	CX	Magee BB and Magee PT, Induction of mating in Candida albicans by construction of MTLa and MTLalpha strains. Science. 2000 Jul 14;289(5477):310-3							
	CY	Mao et al. Overexpre Candida albicans. J E	ssion of a dom acteriol. 1999	inant-negative allele of SI Dec;181(23):7235-42	EC4 inhibits growth and pro	tein secretio	ein secretion in		
	CZ	Mendoza et al. Translation elongation factor 2 is encoded by a single essential gene in Candida albicans. Gene. 1999 Mar 18;229(1-2):183-91							
	DA	Mio et al. Isolation of the Candida albicans homologs of Saccharomyces cerevisiae KRE6 and SKN1: expression and physiological function. J Bacteriol. 1997 Apr;179(7):2363-72							
	DB	Mio et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis. J Bacteriol. 1997 Jul;179(13):4096-105							
	DC	Munro et al. Chs1 of Candida albicans is an essential chitin synthase required for synthesis of the septum and for cell integrity. Mol Microbiol. 2001 Mar;39(5):1414-26							
	DD	Nakayama et al. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun. 2000 Dec;68(12):6712-9							
	DE	Pla et al. Understanding Candida albicans at the molecular level. Yeast. 1996 Dec;12(16):1677-702.							
	DF Shoemaker et al., Quantitative phenotypic analysis of yeast deletion mutants using a hibar-coding strategy. Nat Genet. 1996 Dec;14(4):450-6								
	DG	coexpression of the Penicillium italicum eburicol 14 alpha-demethylase (cyp51) and the A. niger cytochrome P450 reductase (cprA) genes. J Biotechnol. 1996 Aug 20;49(1-3):13-8 Wenkateswarlu et al. NADPH cytochrome P-450 oxidoreductase and susceptibility to ketoconazole. Anixii Agents Chemother. 1998 Jul;42(7):1756-61							
	DH								
	DI								
	DJ				n Saccharomyces cerevisiae es from various organisms.				
EXAMIN	ER			DATE CON	NSIDERED				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.